Another alteration associated with response to therapy is represented by the presence of BRCA mutations, in particular BRCA1. Indeed, it has been shown that BC patients with low/intermediate mRNA levels of BRCA1 receiving neoadjuvant platinum-based therapies presented increased tumor pathological response and OS in comparison with patients with high mRNA BRCA1 levels [60]. This evidence concerns the gene BRCA1 and neoplasm.